Loading...
Adaptive Biotechnologies Community
NasdaqGS:ADPT Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
Community Investing Ideas
ADPT: Leadership In Cancer Testing Will Drive Market Expansion And Execution Risks
Key Takeaways Expansion of clonoSEQ integration and higher reimbursement rates position the company for strong recurring revenue growth and improved gross margins. Advances in clinical and AI-driven immune medicine pipelines create future opportunities in pharma partnerships and innovative diagnostics, supporting long-term earnings potential.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$19.14
14.7% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
14.01% p.a.
Profit Margin
15.7%
Future PE
68.81x
Share price in 2028
US$23.93
Precision Medicine And Immune Sequencing Will Expand Diagnostic Horizons
Key Takeaways Rapid payer adoption and expanded coverage for clonoSEQ are driving significant revenue and margin growth beyond market expectations. Leadership in innovative diagnostics and expanding indications are diversifying revenue streams, supporting sustained test growth and long-term financial upside.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$15
8.8% overvalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
23.42% p.a.
Profit Margin
14.21%
Future PE
56.65x
Share price in 2028
US$18.56
